An observational study in Pregnant With Complication, Preeclampsia and Preterm Birth, sponsored by Gene Solutions. Enrolling by invitation at 1 site in Vietnam. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-16.
Sponsored by Gene Solutions · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is Observational study, aiming to investigate the potentiality of cffDNA and cfRNA by a non-invasive test, in combination with clinical characteristics, to establish models for early screening and predicting high-risk pregnancy of PE, SPB, and GDM in Vietnam.
This study is estimated to enroll 663 pregnant women with adverse pregnancy complications, including 221 cases of PE/eclampsia, 221 cases of SPB due to Preterm premature rupture of membranes (PPROM) or preterm labor, and 221 cases of GDM. Furthermore, the control group will enroll 442 participants, who are healthy pregnancies, ≥ 37 weeks of gestation. Study subjects who participate should meet the study inclusion and exclusion criteria:
As part of the protocol, demographic data, medical and family history, outcomes at delivery, and any relevant prior concomitant medication data will be recorded during follow-up visits. All participants are to be followed until birth delivery.
SAMPLE COLLECTION
The study end date of a participant is estimated within 7 months since her enrollment date.
411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.
This study's planned enrollment of 1,105 is above the median of 400 across 198 observational studies indexed under Pregnancy Complications.
Browse Pregnancy Complications studies →Gene Solutions is the lead sponsor of 9 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study population will include women with singleton pregnancies, who are diagnosed Preeclampsia/eclampsia, Preterm premature rupture of membranes (PPROM)/preterm labor leading to SPB, and/or gestational diabetes mellitus or who are healthy pregnancy at ≥ 37 weeks of gestation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At recruitment, women with singleton pregnancies must fulfill the conditions:
Cases: diagnosis of Preeclampsia/eclampsia, Preterm premature rupture of membranes (PPROM)/preterm labor leading to SPB, and/or gestational diabetes mellitus.
Controls: healthy pregnancy at ≥ 37 weeks of gestation
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Characteristics of pregnant women at 1st trimester (9-13 weeks 6 days of gestation)
Observe the characteristics of pregnant women at 1st trimester (9-13 weeks 6 days of gestation): clinical features, cffDNA, cfRNA
Time frame: 12 months
Characteristics of pregnant women at recruitment
Characteristics of pregnant women at recruitment: clinical features, cffDNA, cfRNA
Time frame: 12 months
Define the significant differences between cases and controls
Comparison between clinical features, cffDNA, and cfRNA of early pregnancy and at recruitment, then defines the significant differences between cases and controls
Time frame: 12 months
The development of learning machine models
The development of learning machine models involved potential factors that help predict events of interest (PE, SPB, and GDM). From cfRNA and cfDNA data, factors that differ between the two groups will be identified and evaluated for their potentiality in predicting high-risk individuals. The Receiver Operating Characteristic (ROC) curve and values of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were used to determine the validity of the constructed model.
Time frame: 12 months
Evaluation of the developed models
Evaluation of the developed models by determining their sensitivity, specificity, area under the ROC Curve (AUC), positive predictive value (PPV), negative predictive value (NPV), and accuracy.
Time frame: 12 months
Plan to share: Yes — Anonymized data of this study may be requested for publication by the journals. Sharing anonymized data with suitable study will be decided by the Sponsor, Principles Investigator and the authority agency. No identifiable information will be share with any other person or organization than authorized in this study.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: December 2025
Access criteria: GS_NP1
Started May 2024 (actual). Primary completion is estimated for Nov 2025, 17 months after the start.
Of 121 observational studies under Pregnancy Complications, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 201. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gene Solutions